Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANAPEM
2025-521478-32-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2026
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myocarditis comparing Anakinra + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Proportion of children with recovered left ventricular ejection fraction at 3 days. Planned start Oct 2026; status: authorised.
02
Drugs
anakinra
03
Conditions
acute myocarditis
Beyond the preview
Go deeper on 2025-521478-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521478-32-00.